{"filings":[{"id":805637,"accession_number":"0001193125-26-253436","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-06-02T20:01:14+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Forte Biosciences stockholders approve amended equity plan adding 1.85M new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved A&R 2021 Equity Incentive Plan with 1,850,000 newly requested shares; total reserve 5,190,000.","Class III directors elected: Steven Kornfeld, Scott Brun, Paul A. Wagner (vote results provided).","Advisory vote on named executive officer compensation for FY2025 passed (12.1M for, 3.8M against, 1.5M broker non-votes).","KPMG ratified as independent auditor for FY2026 (17.7M for, 3K against, 40K abstentions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443956,"accession_number":"0001193125-26-224214","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-05-14T20:42:13+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.","FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.","Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.","R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.","In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92742,"accession_number":"0001193125-26-148796","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences prices $150M public offering of 5.7M shares at $26.27/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing of 5,709,936 shares at $26.27 per share for gross proceeds of ~$150M.","Underwriters have 30-day option to buy up to 856,490 additional shares.","Offering expected to close April 10, 2026; net proceeds ~$141M.","Proceeds to fund working capital and clinical development of autoimmune product candidate.","Strategic investment from argenx BV noted; Guggenheim and Barclays are joint book-runners."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92741,"accession_number":"0001193125-26-135767","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.","Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.","Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.","Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120097,"accession_number":"0001193125-25-281807","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.","R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.","Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.","FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.","Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136675,"accession_number":"0001193125-25-180771","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q2 net loss $0.96/share; $106.1M cash; three FB102 trials on track for 2026 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.96) vs $(6.78) YoY; R&D expenses $8.6M up from $5.7M driven by clinical trials.","Cash and cash equivalents $106.1M; raised $69.9M net in June 2025 offering plus $1.7M overallotment.","Phase 2 celiac disease trial dosing; topline data expected 2026; phase 1b vitiligo data 1H26; alopecia areata initiated with 2026 data.","Shares outstanding: 12.3M common stock and 5.4M pre-funded warrants as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153887,"accession_number":"0001193125-25-147017","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences prices $75M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 5,630,450 shares at $12.00/share and 619,606 pre-funded warrants at $11.999/warrant.","Gross proceeds expected ~$75M; net ~$70M (or ~$80.5M if underwriters' option exercised).","Proceeds for working capital, general corporate purposes, funding clinical/preclinical development.","Offering expected to close June 26, 2025, subject to customary closing conditions.","Underwriters granted 30-day option to purchase up to 937,508 additional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153886,"accession_number":"0001193125-25-144174","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Forte Biosciences reports positive Phase 1b data for FB102 in celiac disease; Phase 2 initiating","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Composite histological VCIEL endpoint met: FB102 mean change 0.079 vs placebo -1.849 (p=0.0099).","CD3+ IELs declined by 1.5 on FB102 vs increase of 13.3 for placebo (p=0.0035).","Gluten challenge GI symptom events per subject: 4.0 for FB102 vs 6.9 for placebo (42% benefit).","No grade 3+ SAEs in FB102 arm; all TEAEs mild; no dropouts.","Phase 2 celiac trial initiating; topline readout expected in 2026; vitiligo readout H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153885,"accession_number":"0001193125-25-131525","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Forte Biosciences annual meeting elects directors; auditor ratification approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Richard Vincent, Shiv Kapoor, and David Gryska as Class II directors until 2028.","David Gryska received 2,786,414 votes for and 1,313,237 withheld (32% withheld).","Ratified KPMG LLP as independent auditor for FY2025 with 5,285,363 votes for, 2,987 against.","5,288,388 shares represented out of 6,583,382 outstanding (80.3% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153884,"accession_number":"0001193125-25-120772","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences Q1 net loss $1.37/share; FB102 celiac data expected, vitiligo trial dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share ($1.37) vs ($4.03) YoY; net loss $15.7M on R&D spend of $12.7M.","Cash $45.9M at March 31, 2025, up from $22.2M at year-end 2024.","FB102 celiac disease topline data planned for Q2 2025; first vitiligo patient dosed.","R&D expenses $12.7M (+188% YoY) driven by manufacturing and clinical trial costs.","Shares outstanding 6.6M plus 4.8M pre-funded warrants as of March 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153883,"accession_number":"0001193125-25-085762","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Forte Biosciences sets annual meeting for May 29, 2025; proposals due April 28","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for May 29, 2025, more than 30 days before the 2024 anniversary.","Stockholder proposals for proxy inclusion must be received by April 28, 2025.","Director nominations and other proposals (non-14a-8) due no later than April 28, 2025.","Universal proxy rule compliance notices for soliciting support of non-company nominees due April 28, 2025.","Prior deadlines for stockholder submissions are no longer applicable due to the revised meeting date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153882,"accession_number":"0001193125-25-073403","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-04-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.","Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.","FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.","First FB102 vitiligo patient dosing expected shortly."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172550,"accession_number":"0001193125-25-012236","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2025-01-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Forte Biosciences stockholders approve amended equity plan adding 3.34M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved A&R 2021 Equity Incentive Plan on Jan 24, 2025; 2.19M for, 0.47M against, 1.38M abstain.","Plan adds 3,340,000 shares to reserve plus up to 44,093 from forfeited prior plan awards.","Plan authorizes grants of options, SARs, restricted stock, RSUs, performance awards to employees, directors, consultants.","Plan prohibits Exchange Programs (no repricing or cancellation of underwater awards without shareholder approval)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189542,"accession_number":"0001193125-24-269949","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Forte Biosciences hosts R&D Day focusing on FB102 autoimmune updates","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["R&D Day held December 3, 2024 highlighting FB102 development in autoimmune indications.","Slide deck (Ex-99.1) and updated corporate presentation (Ex-99.2) furnished with the filing.","No specific clinical data or financial guidance disclosed in the 8-K or exhibits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189541,"accession_number":"0001193125-24-262543","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Forte Biosciences raises $53M in oversubscribed private placement for FB102 clinical development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$53M from shares and pre-funded warrants to institutional investors including OrbiMed, Janus Henderson, Tybourne.","Private placement expected to close November 21, 2024; net proceeds for working capital and general corporate purposes.","FB102 healthy volunteer study completed; celiac disease trial topline readout projected Q2 2025.","Additional indications expected over next 12 months; R&D Day on December 3, 2024.","CEO Paul Wagner says financing is transformative and well capitalized for continued advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189540,"accession_number":"0001193125-24-258537","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosing begun in celiac disease trial; topline data expected Q2 2025.","Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.","Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).","Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206041,"accession_number":"0001193125-24-222962","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Forte Biosciences appoints Richard Vincent and Shiv Kapoor to board; settles Camac lawsuit for $1.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald A. Williams and Lawrence Eichenfield resigned from board effective Sept 17, 2024, not due to any disagreement.","Richard Vincent and Shiv Kapoor appointed as Class II directors; to stand for election at 2025 annual meeting.","Steven Kornfeld and Scott Brun reclassified from Class II to Class III to maintain class sizes.","Camac Fund lawsuit settled; company to pay $1.5M for attorneys' fees; case dismissed with prejudice as to Camac; Standstill Agreement stands.","Board established Strategic Committee of independent directors; Rights Agreement (poison pill) expired July 12, 2024, not renewed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206040,"accession_number":"0001193125-24-211066","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Forte Biosciences implements 1-for-25 reverse stock split effective August 28, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-25 ratio effective 8:00 a.m. ET on August 28, 2024.","No fractional shares issued; cash paid for fractional shares based on Aug 27 closing price.","CUSIP changed to 34962G 208; trading symbol FBRX unchanged on Nasdaq.","Proportionate adjustments made to equity incentive plans and outstanding awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206039,"accession_number":"0001193125-24-205350","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Forte Biosciences secures shareholder approval for 1-for-25 reverse split effective Aug 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio set at 1-for-25; effective Aug 28, 2024, with new CUSIP 34962G 208.","Stockholders approved amendment to effect reverse split (26.7M for, 2.1M against).","Amended 2021 Equity Incentive Plan approved (17.3M for, 6.9M against); adds up to 8.5M new shares plus up to 1.1M from prior plans.","Class I directors elected: Barbara K. Finck, M.D. (18.8M for), Donald A. Williams (15.4M for), Stephen K. Doberstein (15.1M for).","KPMG LLP ratified as independent auditor for FY2024 with 28.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206038,"accession_number":"0001193125-24-200673","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).","Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).","FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.","Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.","G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223064,"accession_number":"0001193125-24-161592","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.","Strategic alternatives committee formed including Camac nominees; rights plan expires July 12, 2024, not renewed, no new plan for 3 years.","Camac enters standstill/voting agreement through 2028; company pays $364k for Camac's 2023 proxy contest out-of-pocket expenses.","Settlement resolves claims that July 2023 private placement (~$25M) was intended to entrench board and block Camac director nominees.","The standstill prohibits Camac from acquiring additional shares, launching proxy contests, or seeking board representation until 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223063,"accession_number":"0001193125-24-137210","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences Q1 net loss $0.16/shr; cash $30.4M; FB102 SAD completed, MAD ongoing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $7.4M ($0.16/shr) vs $6.8M ($0.32/shr) in Q1 2023; weighted avg shares 46.1M (incl. pre-funded warrants).","R&D expense $4.4M (down $0.4M); G&A $3.5M (up $1.4M on legal/professional costs).","Cash & equivalents $30.4M at Mar 31, 2024, down from $37.1M at Dec 31, 2023.","FB102 Phase 1 SAD completed; MAD cohorts expected to complete mid-2024; patient studies planned before year-end.","Company updated corporate presentation (Exhibit 99.2) for investor meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242554,"accession_number":"0001193125-24-070158","cik":1419041,"company_name":"Forte Biosciences, Inc.","ticker":"FBRX","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Forte Biosciences reports FY 2023 net loss of $31.5M; FB-102 advances to MAD cohort","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M ($1.00 per share) vs. $13.9M ($0.80) in FY 2022, driven by increased R&D spend.","R&D expenses rose to $21.9M from $5.6M, primarily due to FB-102 manufacturing and clinical costs.","Cash and equivalents of $37.1M at year-end 2023, down from $41.1M at end of 2022.","FB-102 Phase 1 SAD portion completed; multiple ascending dose (MAD) cohorts now dosing.","Shares outstanding of 36.3M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":429952749.2345133,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}